Population
1 poliomyelitis patient from Taiwan with common variable immunodeficiency; PVR-Tg21 transgenic mice used for…
Design
Case_report
Follow-up
337-day period for isolate collection; 30 to 35 months of…
Authors
Loading...
May signal prolonged neurovirulent iVDPV shedding risks in immunodeficient patients; leaves open post-eradication OPV strategies.
The emergence of distinct coreplicating lineages of vaccine-derived poliovirus in a chronically infected immunodeficient patient highlights the risk of prolonged viral shedding and has implications for stopping OPV immunization post-eradication.
Yang et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: